| Age (continuous) |
1.00 (0.96−1.03) |
0.80 |
|
− |
− |
| Gender |
0.54 (0.23−1.28) |
0.16 |
|
− |
− |
| Histology (other vs. adenocarcinoma) |
1.62 (0.78−3.37) |
0.20 |
|
− |
− |
| Location (vs. supratentorial) |
|
|
|
|
|
| Infratentorial |
1.70 (0.82−3.53) |
0.16 |
|
− |
− |
| Both |
0.96 (0.27−2.12) |
0.92 |
|
− |
− |
| Initial primary tumor stage (vs. IV) |
|
|
|
|
|
| I |
0.93 (0.27−3.21) |
0.91 |
|
− |
− |
| II |
0.85 (0.40−1.82) |
0.67 |
|
− |
− |
| III |
1.39 (0.64−3.03) |
0.41 |
|
− |
− |
| Unknown |
0.58 (0.17−1.99) |
0.39 |
|
− |
− |
| Definitive primary therapy (vs. chemotherapy) |
0.89 (0.46−1.73) |
0.37 |
|
− |
− |
| Time to diagnosis of brain metastasis from original diagnosis (continuous) |
1.00 (0.98−1.03) |
0.79 |
|
− |
− |
| Number of brain metastases (vs. 1) |
|
|
|
|
|
| 2 |
0.97 (0.46−2.02) |
0.93 |
|
0.90 (0.43−1.89) |
0.77 |
| 3 or more |
5.70 (2.51−13.0) |
<0.01 |
|
4.77 (1.99−11.4) |
<0.01 |
| RPA classification (vs. I) |
|
|
|
|
|
| II |
1.37 (0.69−2.73) |
0.36 |
|
1.42 (0.71−2.84) |
0.32 |
| III |
8.22 (2.76−24.4) |
<0.01 |
|
4.77 (1.99−11.4) |
<0.01 |
| KPS <70 (vs. ≥70) |
6.60 (2.50−17.4) |
<0.01 |
|
− |
− |
| Controlled primary (vs. uncontrolled) |
0.79 (0.44−1.42) |
0.43 |
|
− |
− |
| No extracranial metastasis (vs. yes) |
1.54 (0.85−2.78) |
0.16 |
|
− |
− |
| Age <65 (vs. ≥65) |
0.97 (0.49−1.92) |
0.93 |
|
− |
− |
